Tower Research Capital (TRC)’s Fortress Biotech FBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.3K | Sell |
1,404
-9,091
| -87% | -$23.4K | ﹤0.01% | 4406 |
|
|
2026
Q1 | $29.3K | Buy |
+10,495
| New | +$35.7K | ﹤0.01% | 3192 |
|
|
2025
Q4 | – | Sell |
-4,783
| Closed | -$17.7K | – | 5276 |
|
|
2025
Q3 | $17.7K | Buy |
4,783
+3,879
| +429% | +$9.81K | ﹤0.01% | 3419 |
|
|
2025
Q2 | $1.68K | Buy |
+904
| New | +$1.57K | ﹤0.01% | 4764 |
|
|
2025
Q1 | – | Sell |
-1,973
| Closed | -$4K | – | 5363 |
|
|
2024
Q4 | $4K | Sell |
1,973
-1,523
| -44% | -$2.76K | ﹤0.01% | 4544 |
|
|
2024
Q3 | $5.05K | Buy |
3,496
+2,536
| +264% | +$4.83K | ﹤0.01% | 4337 |
|
|
2024
Q2 | $1.64K | Buy |
+960
| New | +$1.74K | ﹤0.01% | 5118 |
|
|
2024
Q1 | – | Sell |
-198
| Closed | -$596 | – | 5948 |
|
|
2023
Q4 | $596 | Sell |
198
-1,892
| -91% | -$5K | ﹤0.01% | 5530 |
|
|
2023
Q3 | $9.09K | Buy |
2,090
+506
| +32% | +$3.47K | ﹤0.01% | 4266 |
|
|
2023
Q2 | $13.1K | Buy |
1,584
+537
| +51% | +$5.31K | ﹤0.01% | 3806 |
|
|
2023
Q1 | $13K | Buy |
1,047
+986
| +1,616% | +$11.7K | ﹤0.01% | 3962 |
|
|
2022
Q4 | $1K | Buy |
+61
| New | +$675 | ﹤0.01% | 5584 |
|
|
2022
Q3 | – | Sell |
-144
| Closed | -$2K | – | 6172 |
|
|
2022
Q2 | $2K | Sell |
144
-504
| -78% | -$7.47K | ﹤0.01% | 5533 |
|
|
2022
Q1 | $13K | Buy |
648
+415
| +178% | +$11.4K | ﹤0.01% | 3974 |
|
|
2021
Q4 | $9K | Sell |
233
-1,479
| -86% | -$66K | ﹤0.01% | 4687 |
|
|
2021
Q3 | $82K | Buy |
1,712
+1,400
| +449% | +$68.3K | ﹤0.01% | 2565 |
|
|
2021
Q2 | $17K | Sell |
312
-594
| -66% | -$35.8K | ﹤0.01% | 4037 |
|
|
2021
Q1 | $48K | Buy |
906
+294
| +48% | +$16.6K | ﹤0.01% | 3156 |
|
|
2020
Q4 | $29K | Sell |
612
-3,193
| -84% | -$138K | ﹤0.01% | 3592 |
|
|
2020
Q3 | $231K | Buy |
3,805
+3,612
| +1,872% | +$184K | ﹤0.01% | 2439 |
|
|
2020
Q2 | $8K | Buy |
+193
| New | +$7.17K | ﹤0.01% | 4101 |
|
|
2020
Q1 | – | Sell |
-417
| Closed | -$16K | – | 3282 |
|
|
2019
Q4 | $16K | Sell |
417
-3,371
| -89% | -$86.5K | ﹤0.01% | 2061 |
|
|
2019
Q3 | $80K | Buy |
+3,788
| New | +$89.1K | 0.01% | 1486 |
|
|
2019
Q2 | – | Sell |
-398
| Closed | -$10K | – | 3857 |
|
|
2019
Q1 | $10K | Buy |
398
+297
| +294% | +$7.79K | ﹤0.01% | 2673 |
|
|
2018
Q4 | $1K | Sell |
101
-1,442
| -93% | -$24.1K | ﹤0.01% | 3578 |
|
|
2018
Q3 | $37K | Buy |
+1,543
| New | +$49.4K | ﹤0.01% | 1950 |
|
|
2018
Q2 | – | Sell |
-182
| Closed | -$12K | – | 3760 |
|
|
2018
Q1 | $12K | Buy |
182
+82
| +82% | +$5.19K | ﹤0.01% | 2389 |
|
|
2017
Q4 | $6K | Sell |
100
-189
| -65% | -$11.1K | ﹤0.01% | 2810 |
|
|
2017
Q3 | $19K | Buy |
+289
| New | +$19.5K | ﹤0.01% | 2756 |
|
|
2016
Q2 | – | Sell |
-85
| Closed | -$4K | – | 4572 |
|
|
2016
Q1 | $4K | Buy |
85
+14
| +20% | +$591 | ﹤0.01% | 2877 |
|
|
2015
Q4 | $3K | Buy |
71
+54
| +318% | +$2.26K | ﹤0.01% | 3427 |
|
|
2015
Q3 | $1K | Sell |
17
-336
| -95% | -$15.7K | ﹤0.01% | 3599 |
|
|
2015
Q2 | $18K | Sell |
353
-1,860
| -84% | -$95.5K | ﹤0.01% | 2177 |
|
|
2015
Q1 | $127K | Buy |
2,213
+2,197
| +13,731% | +$91.6K | 0.02% | 708 |
|
|
2014
Q4 | $1K | Buy |
+16
| New | +$471 | ﹤0.01% | 3629 |
|
|
2014
Q3 | – | Sell |
-661
| Closed | -$18K | – | 4523 |
|
|
2014
Q2 | $18K | Sell |
661
-419
| -39% | -$11K | ﹤0.01% | 1903 |
|
|
2014
Q1 | $32K | Buy |
+1,080
| New | +$42.1K | ﹤0.01% | 1435 |
|
|
2013
Q4 | – | Sell |
-543
| Closed | -$57K | – | 4598 |
|
|
2013
Q3 | $57K | Buy |
+543
| New | +$66.6K | 0.01% | 1794 |
|
Other funds holding FBIO
OM
GCP
SAM
BCM
Tower Research Capital (TRC)'s FBIO Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Fortress Biotech (FBIO) stake by 87% in Q2 2026, selling an estimated $23.4K and leaving 1,404 shares worth $4.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4406.
Tower Research Capital (TRC) first reported a position in FBIO in Q3 2013 and has held it in 38 quarters since. The position peaked at $231K in Q3 2020. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.
- Tower Research Capital (TRC) held 1,404 shares of Fortress Biotech worth $4.3K as of Q2 2026.
- Tower Research Capital (TRC) sold 9,091 Fortress Biotech shares in Q2 2026, an estimated $23.4K.
- Fortress Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4406 holding.
- Tower Research Capital (TRC) first reported a position in Fortress Biotech in Q3 2013 and has held it in 38 quarters since.
- Tower Research Capital (TRC)'s Fortress Biotech position peaked at $231K in Q3 2020.
- 55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.